ocjenjiv najviše identifikacija spartan trial Veliki koraljni greben osim za Iskreno
ASCO-GU 2023: Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-hoc analysis of the SPARTAN phase III trial.
Efficacy | ERLEADA® (apalutamide) HCP
NEJM al Twitter: "Among men with non-metastatic castration-resistant #prostatecancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. Full SPARTAN trial results: https://t.co ...
Mauricio Z. Baptista on Twitter: "SPARTAN Ph3 Rand Trial of Apalutamide vs Placebo in non mCRPC, Survival Results, New SOC is coming, #GU18 #pcsm #prostatecancer https://t.co/qG8gT3ke1W" / Twitter
ESMO 2019: Invited Discussant – An Update on the Phase 3 SPARTAN Study and Long-term Outcomes for M1 Patients in the STAMPEDE Randomized Trial – Philippine Endourological Society
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Spartan - Speed meets obstacles. Race against the best in our Time Trial course Friday 6pm. | Facebook
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Treating Non-Metastatic CRPC: The Evolving Landscape
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
Updates and Insights on the Medical Science of Prostate Cancer - ppt download
Phase 3 SPARTAN Trial in nmCRPC
TAILOR-PCI is the largest trial of... - Spartan Bioscience | Facebook
Apalutamide in metastatic castration resistant prostate cancer
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
ASCO 2019: Age-Related Efficacy and Safety of Apalutamide plus Ongoing Androgen Deprivation Therapy in Subgroups of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of SPARTAN
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Cancer Trial Results
Mauricio Z. Baptista on Twitter: "SPARTAN Ph3 Rand Trial of Apalutamide vs Placebo in non mCRPC, Survival Results, New SOC is coming, #GU18 #pcsm #prostatecancer https://t.co/qG8gT3ke1W" / Twitter
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
Page 46 - Monitoring Prostate Cancer to Guide Treatment Decision-Making
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM